Boylan K, Walz C, Schefter A, Skubitz A
Cancers (Basel). 2025; 17(5).
PMID: 40075748
PMC: 11899234.
DOI: 10.3390/cancers17050901.
Kurelac I, Sollazzo M, De Luise M, Nanetti F, Lanteri L, DAngelo L
Front Mol Biosci. 2025; 12:1537407.
PMID: 40051502
PMC: 11882402.
DOI: 10.3389/fmolb.2025.1537407.
Powell L, Quintela M, James D, Onyido E, Howard D, Edwards K
Front Cell Dev Biol. 2025; 13:1450407.
PMID: 39974724
PMC: 11836028.
DOI: 10.3389/fcell.2025.1450407.
Meunier A, Hernandez-Castro J, Chahley N, Communal L, Kheireddine S, Koushki N
Commun Med (Lond). 2025; 5(1):33.
PMID: 39900650
PMC: 11790846.
DOI: 10.1038/s43856-024-00702-9.
Wesley T, Escalona R, Kannourakis G, Ahmed N
Cancers (Basel). 2024; 16(23).
PMID: 39682273
PMC: 11639978.
DOI: 10.3390/cancers16234087.
Beyond tumor‑associated macrophages involved in spheroid formation and dissemination: Novel insights for ovarian cancer therapy (Review).
Liu Y, Xiao H, Zeng H, Xiang Y
Int J Oncol. 2024; 65(6).
PMID: 39513610
PMC: 11575928.
DOI: 10.3892/ijo.2024.5705.
Multifaceted cancer alleviation by cowpea mosaic virus in a bioprinted ovarian cancer peritoneal spheroid model.
Xiang Y, Zhao Z, Yao E, Balayan A, Fiering S, Steinmetz N
Biomaterials. 2024; 311():122663.
PMID: 38878481
PMC: 11729462.
DOI: 10.1016/j.biomaterials.2024.122663.
Characterization of EpCAM in thyroid cancer biology by three-dimensional spheroids in vitro model.
Ghiandai V, Grassi E, Gazzano G, Fugazzola L, Persani L
Cancer Cell Int. 2024; 24(1):196.
PMID: 38835027
PMC: 11149206.
DOI: 10.1186/s12935-024-03378-2.
Engineered CAR-T cells targeting the non-functional P2X purinoceptor 7 (P2X7) receptor as a novel treatment for ovarian cancer.
Bandara V, Niktaras V, Willett V, Chapman H, Lokman N, Macpherson A
Clin Transl Immunology. 2024; 13(5):e1512.
PMID: 38800555
PMC: 11116765.
DOI: 10.1002/cti2.1512.
The role of Piezo1 mechanotransduction in high-grade serous ovarian cancer: Insights from an in vitro model of collective detachment.
Micek H, Yang N, Dutta M, Rosenstock L, Ma Y, Hielsberg C
Sci Adv. 2024; 10(17):eadl4463.
PMID: 38669327
PMC: 11051664.
DOI: 10.1126/sciadv.adl4463.
EM-transcriptomic signature predicts drug response in advanced stages of high-grade serous ovarian carcinoma based on ascites-derived primary cultures.
Constantinescu D, Sorop A, Ghionescu A, Lixandru D, Herlea V, Bacalbasa N
Front Pharmacol. 2024; 15:1363142.
PMID: 38510654
PMC: 10953505.
DOI: 10.3389/fphar.2024.1363142.
A Recipe for Successful Metastasis: Transition and Migratory Modes of Ovarian Cancer Cells.
Sliwa A, Szczerba A, Pieta P, Bialas P, Lorek J, Nowak-Markwitz E
Cancers (Basel). 2024; 16(4).
PMID: 38398174
PMC: 10886816.
DOI: 10.3390/cancers16040783.
Development of adaptive anoikis resistance promotes metastasis that can be overcome by CDK8/19 Mediator kinase inhibition.
Monavarian M, Page E, Rajkarnikar R, Kumari A, Macias L, Massicano F
bioRxiv. 2023; .
PMID: 38106208
PMC: 10723298.
DOI: 10.1101/2023.12.04.569970.
Ovarian cancer relies on the PDGFRβ-fibronectin axis for tumorsphere formation and metastatic spread.
Gendrau-Sanclemente N, Figueras A, Gracova K, Lahiguera A, Alsina-Sanchis E, Marin-Jimenez J
Mol Oncol. 2023; 18(1):136-155.
PMID: 38010623
PMC: 10766197.
DOI: 10.1002/1878-0261.13556.
UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer.
Harrington B, Kamdar R, Ning F, Korrapati S, Caminear M, Hernandez L
J Exp Clin Cancer Res. 2023; 42(1):270.
PMID: 37858159
PMC: 10585874.
DOI: 10.1186/s13046-023-02820-z.
Matriptase drives dissemination of ovarian cancer spheroids by a PAR-2/PI3K/Akt/MMP9 signaling axis.
Pawar N, Buzza M, Duru N, Strong A, Antalis T
J Cell Biol. 2023; 222(11).
PMID: 37737895
PMC: 10515437.
DOI: 10.1083/jcb.202209114.
A comparative analysis of 2D and 3D experimental data for the identification of the parameters of computational models.
Cortesi M, Liu D, Yee C, Marsh D, Ford C
Sci Rep. 2023; 13(1):15769.
PMID: 37737283
PMC: 10517149.
DOI: 10.1038/s41598-023-42486-3.
Ascitic autotaxin as a potential prognostic, diagnostic, and therapeutic target for epithelial ovarian cancer.
Choi J, Kim H, Kwon H, Lee E, Cho H, Chung J
Br J Cancer. 2023; 129(7):1184-1194.
PMID: 37596406
PMC: 10539369.
DOI: 10.1038/s41416-023-02355-2.
Gain-of-function p53 blocks apoptosis in a precursor model of ovarian high-grade serous carcinoma.
Haagsma J, Kolendowski B, Buensuceso A, Valdes Y, DiMattia G, Shepherd T
Sci Rep. 2023; 13(1):11424.
PMID: 37452087
PMC: 10349050.
DOI: 10.1038/s41598-023-38609-5.
Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches.
Lucic I, Kurtovic M, Mlinaric M, Pitesa N, cipak Gasparovic A, Sabol M
Int J Mol Sci. 2023; 24(13).
PMID: 37445860
PMC: 10342190.
DOI: 10.3390/ijms241310683.